The development of new therapies for human herpesvirus 6

Current Opinion in Virology

Volumn 9, Issue , 2014, Pages 148-153

  Prichard, Mark N ^b   Whitley, Richard J ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAZOLE DERIVATIVE; BRINCIDOFOVIR; CIDOFOVIR; CMV423; CYCLOPROPAVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS INFECTION; DNA VIRUS; ELECTROLYTE DISTURBANCE; EXANTHEMA SUBITUM; EXPERIMENTAL THERAPY; HOST CELL; HUMAN; HUMAN HERPESVIRUS 6; NONHUMAN; TOXICITY; DRUG DEVELOPMENT; IMMUNOCOMPROMIZED PATIENT; ISOLATION AND PURIFICATION; ROSEOLOVIRUS INFECTIONS; TRENDS;

ANTIVIRAL AGENTS; DRUG DISCOVERY; HUMANS; IMMUNOCOMPROMISED HOST; ROSEOLOVIRUS INFECTIONS;

EID: 84908400225     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2014.09.019     Document Type: Review

References (68)

1. Zerr DM et al.: A population-based study of primary human herpesvirus 6 infection. N Engl J Med 2005, 352:768-776.
2. Dominguez G et al.: Human herpesvirus 6B genome sequence: coding content and comparison with human herpesvirus 6A. J Virol 1999, 73:8040-8052.
3. Inoue N, Dambaugh TR, Pellett PE: Molecular biology of human herpesviruses 6A and 6B. Infect Agents Dis 1993, 2:343-360.
4. Yamanishi K et al.: Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988, 1:1065-1067.
5. Steeper TA et al.: The spectrum of clinical and laboratory findings resulting from human herpesvirus-6 (HHV-6) in patients with mononucleosis-like illnesses not resulting from Epstein-Barr virus or cytomegalovirus. Am J Clin Pathol 1990, 93:776-783.
6. Smith JM, McDonald RA: Emerging viral infections in transplantation. Pediatr Transplant 2006, 10(7):838-843.
7. Yoshikawa T: Human herpesvirus-6 and -7 infections in transplantation. Pediatr Transplant 2003, 7:11-17.
8. Okuno T et al.: Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J Clin Microbiol 1989, 27:651-653.
9. Santoro F et al.: CD46 is a cellular receptor for human herpesvirus 6. Cell 1999, 99:817-827.
10. Tang H et al.: CD134 is a cellular receptor specific for human herpesvirus-6B entry. Proc Natl Acad Sci U S A 2013, 110:9096-9099.
11. He J et al.: Infection of primary human fetal astrocytes by human herpesvirus 6. J Virol 1996, 70:1296-1300.
12. Isaacson E et al.: Evidence of human herpesvirus 6 infection in 4 immunocompetent patients with encephalitis. Clin Infect Dis 2005, 40:890-893.
13. Soldan SS et al.: Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med 1997, 3:1394-1397.
14. Boeckh M et al.: Emerging viral infections after hematopoietic cell transplantation. Pediatr Transplant 2005, 9(Suppl. 7):48-54.
15. Dulery R et al.: Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol Blood Marrow Transplant 2012, 18:1080-1089.
16. Tokimasa S et al.: Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Bone Marrow Transplant 2002, 29:595-598.
17. Leong HN et al.: The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J Med Virol 2007, 79:45-51.
18. Pellett PE et al.: Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol 2012, 22:144-155.
19. Black JB et al.: Growth properties of human herpesvirus-6 strain Z29. J Virol Methods 1989, 26:133-145.
20. Reymen D et al.: Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Antivir Res 1995, 28:343-357.
21. Ablashi DV et al.: Genomic polymorphism: growth properties, and immunologic variations in human herpesvirus-6 isolates. Virology 1991, 184:545-552.
22. Prichard MN et al.: Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses. Antimicrob Agents Chemother 2013, 57:3518-3527.
23. Manichanh C et al.: Susceptibility of human herpesvirus 6 to antiviral compounds by flow cytometry analysis. Cytometry 2000, 40:135-140.
24. De Clercq E, Naesens L: In search of effective anti-HHV-6 agents. J Clin Virol 2006, 37(Suppl. 1):S82-S86.
25. Gerdemann U et al.: Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood 2013, 121:207-218.
26. Yoshida M et al.: Comparison of antiviral compounds against human herpesvirus 6 and 7. Antivir Res 1998, 40:73-84.
27. De Bolle L et al.: Role of the human herpesvirus 6 u69-encoded kinase in the phosphorylation of ganciclovir. Mol Pharmacol 2002, 62:714-721.
28. De Bolle L et al.: Human herpesvirus 6 infection arrests cord blood mononuclear cells in G(2) phase of the cell cycle. FEBS Lett 2004, 560:25-29.
29. De Bolle L et al.: Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance. Antivir Res 2004, 64:17-25.
30. Manichanh C et al.: Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. J Gen Virol 2001, 82:2767-2776.
31. Ljungman P et al.: Effectiveness of ganciclovir against human herpesvirus-6 excreted in saliva in stem cell transplant recipients. Bone Marrow Transplant 2007, 39:497-499.
32. Kogelnik AM et al.: Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol 2006, 37(Suppl. 1):S33-S38.
33. Mechai F et al.: Human herpesvirus 6-associated retrobulbar optic neuritis in an HIV-infected patient: response to antiherpesvirus therapy and long-term outcome. J Med Virol 2007, 79:931-934.
34. Cacheux W et al.: HHV-6-related acute liver failure in two immunocompetent adults: favourable outcome after liver transplantation and/or ganciclovir therapy. J Intern Med 2005, 258:573-578.
35. Johnston RE et al.: HHV-6-related secondary graft failure following allogeneic bone marrow transplantation. Br J Haematol 1999, 105:1041-1043.
36. Mookerjee BP, Vogelsang G: Human herpes virus-6 encephalitis after bone marrow transplantation: successful treatment with ganciclovir. Bone Marrow Transplant 1997, 20:905-906.
37. Rieux C et al.: Human herpesvirus-6 meningoencephalitis in a recipient of an unrelated allogeneic bone marrow transplantation. Transplantation 1998, 65:1408-1411.
38. Bounaadja L et al.: Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir. J Clin Virol 2013, 58:279-282.
39. Isegawa Y et al.: Human herpesvirus 6 ganciclovir-resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient. J Clin Virol 2009, 44:15-19.
40. Shiraki K et al.: Phosphonoacetic acid inhibits replication of human herpesvirus-6. Antivir Res 1989, 12:311-318.
41. Bethge W et al.: Successful treatment of human herpesvirus-6 encephalitis after bone marrow transplantation. Bone Marrow Transplant 1999, 24:1245-1248.
42. Pohlmann C et al.: Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipient. Clin Infect Dis 2007, 44:e118-e120.
43. Bonnafous P et al.: Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet. Antivir Ther 2007, 12:877-888.
44. Breddemann A et al.: Case report: severe gastrointestinal inflammation and persistent HHV-6B infection in a paediatric cancer patient. Herpes 2007, 14:41-44.
45. Bonnafous P et al.: Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection. Antivir Res 2008, 77:237-240.
46. Hostetler KY: Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antivir Res 2009, 82:A84-A98.
47. Williams-Aziz SL et al.: Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother 2005, 49:3724-3733.
48. Bidanset DJ et al.: Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis 2004, 190:499-503.
49. Quenelle DC et al.: Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004, 48:404-412.
50. Marty FM et al.: CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013, 369:1227-1236.
51. Naesens L et al.: Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts. J Clin Virol 2006, 37(Suppl. 1):S69-S75.
52. De Bolle L et al.: Potent: selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423. Biochem Pharmacol 2004, 67:325-336.
53. Kern ER et al.: In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother 2005, 49:1039-1045.
54. James SH et al.: Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob Agents Chemother 2011, 55:4682-4691.
55. Chou S, Bowlin TL: Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob Agents Chemother 2011, 55:382-384.
56. Gentry BG et al.: Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97. Antimicrob Agents Chemother 2013, 57:4343-4348.
57. Prichard MN: Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol 2009, 19:215-229.
58. Komazin-Meredith G et al.: Human herpesvirus 6 U69 kinase phosphorylates the methylenecyclopropane nucleosides cyclopropavir, MBX 2168, and MBX 1616 to their monophosphates. Antimicrob Agents Chemother 2013, 57:5760-5762.
59. Biron KK et al.: Potent and selective inhibition of human cytomegalovirus replication by 1263W94: a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002, 46:2365-2372.
60. Prichard MN et al.: Benzimidazole analogs inhibit human herpesvirus 6. Antimicrob Agents Chemother 2011, 55:2442-2445.
61. Underwood MR et al.: Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J Virol 1998, 72:717-725.
62. Efferth T et al.: Antiviral activity of artesunate towards wild-type: recombinant, and ganciclovir-resistant human cytomegaloviruses. J Mol Med (Berl) 2002, 80:233-242.
63. Kaptein SJ et al.: The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antivir Res 2006, 69:60-69.
64. Shapira MY et al.: Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008, 46:1455-1457.
65. Wolf DG et al.: Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antivir Res 2011, 90:183-186.
66. Milbradt J et al.: Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum antiinfective drug artesunate. J Clin Virol 2009, 46:24-28.
67. Hakacova N et al.: First therapeutic use of Artesunate in treatment of human herpesvirus 6B myocarditis in a child. J Clin Virol 2013, 57:157-160.
68. Naesens L et al.: Antiviral properties of new arylsulfone derivatives with activity against human betaherpesviruses. Antivir Res 2006, 72:60-67.